Halozyme Therapeutics, Inc. Q3 2025 Earnings Recap

Halozyme achieved record royalty revenues of $236 million in Q3 2025, a 52% year-over-year increase, contributing to total revenue growth of 22% to $354 million, driven by strong performance in its blockbuster subcutaneous therapies.

Key Takeaways

• Adjusted EBITDA surged 35% to $248 million, showcasing robust operational efficiency in a royalty-based model.
• The company raised its full-year 2025 revenue guidance to $1.3-$1.375 billion, reflecting expected royalty revenue growth of 49%-54%.
• Significant regulatory milestones included approvals for DARZALEX in new indications and expand the patient base for ENHANZE-enhanced therapies.
• The recent acquisition of Elektrofi positions Halozyme to broaden its drug delivery technology portfolio and facilitate at-home administration options.